Stock Comparison

URGN vs VRTX

UroGen Pharma Ltd and Vertex Pharmaceuticals Inc side by side — valuation, profitability, growth and risk.

URGN

UroGen Pharma Ltd

Healthcare

VRTX

Vertex Pharmaceuticals Inc

Healthcare

Valuation

Market Cap

$2.38B

$123.94B

P/E (TTM)

—

28.5

Forward P/E

—

25.7

Price/Sales

12.6

9.9

Price/Book

16.9

6.1

EV/EBITDA

-2.7

23.2

Dividend Yield

—

Profitability

Net Margin

-94.83%

35.40%

Operating Margin

-77.02%

38.97%

Return on Equity

-1481.00%

23.50%

Return on Assets

-18.10%

11.90%

Growth (YoY)

Revenue Growth

199.20%

12.50%

Earnings Growth

0.00%

8.00%

Price & Risk

Beta

1.6

0.3

52-Week High

$49.00

$529.65

52-Week Low

$16.42

$376.62

Analyst Target

$58.25

$559.28

Compare URGN and VRTX your own way

Try mrmarket.ai free

Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.